Recurrent Implantation Failure Clinical Trial
Official title:
The Value of Atosiban on the Day of Embryo Transfer in Patients With Recurrent Implantation Failure
ET is the final stage of IVF which independently influences the treatment outcome. Successful embryo implantation is dependent on uterine receptivity. Atosiban is a novel class of drug which is effective in priming the uterus for implantation. It reduces uterine contractions and increases endomyometrial perfusion, both of which have potential benefits regarding improved IRs, CPR, and ongoing pregnancy rates. Atosiban has a good embryonic safety profile. It has no systemic toxicity, no mutagenic effects, and no carcinogenic effects
ET is a critical step of an IVF cycle that merits the utmost attention. Its success depends on the frequency of uterine contractions, the endometrial receptivity and the quality of embryos transferred. Uterine contractions are the most fundamental constituents of the uterine receptivity. Excessive contractions may decrease the implantation potential of embryos by expelling the embryos from the uterus. Studies have revealed a six-fold increase in uterine contractility in IVF cycles when measured before ET as compared to the condition before ovulation in natural cycles. Excessive manipulation of the cervix such as the use of tenaculum during difficult ET can also trigger uterine contractions, consequently leading to failure of embryo implantation. IVF success rates have been potentially improved by the use of drugs that inhibit pronounced uterine contractions at the time of ET. Treatment strategies such as the use of beta-agonists or nonsteroidal anti-inflammatory agents for tocolysis have not been beneficial in IVF-ET procedures. Atosiban is a combined oxytocin/vasopressin V1A antagonist. It functions mainly by blocking oxytocin and vasopressin V1a receptors to decrease the frequency and amplitude of uterine contractions, which enhances implantation and pregnancy rates. RIF remains unexplained in most cases, which results in considerable variation in how RIF is treated and managed. Atosiban competes with oxytocin at oxytocin receptors in endometrial cells and inhibits oxytocin-induced PGF2α release, thus inhibiting uterine contractions and increasing chances of embryo implantation and may add value in improving the outcome in RIF patients. Recently published studies showed that atosiban inhibits oxytocin-induced PGF2α and uterine contractility, consequently leading to improved IRs. Studies have shown a considerable reduction in the frequency of uterine contractions before and after the administration of atosiban in women undergoing ET. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03660735 -
The PIP Study - Pre- IVF Immune Profiling Study
|
||
Not yet recruiting |
NCT04528277 -
Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
|
Phase 3 | |
Recruiting |
NCT04998279 -
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women With History of RIF
|
||
Completed |
NCT03267797 -
hCG-activated PBMC-therapy in RIF Patients
|
N/A | |
Recruiting |
NCT05343572 -
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
|
Early Phase 1 | |
Not yet recruiting |
NCT02752568 -
Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure
|
N/A | |
Recruiting |
NCT04822207 -
Effect of Acupuncture on the Clinical Outcome of IVF-ET in Patients With Recurrent Implantation Failure
|
N/A | |
Recruiting |
NCT03900780 -
Preimplantation Genetic Testing for Aneuploidies in Patients With Recurrent Implantation Failure
|
N/A | |
Not yet recruiting |
NCT03549728 -
Effect of Granulocyte Colony-stimulating Factor on Clinical Pregnancy Rate in Patients With Endometriosis
|
Phase 2 | |
Completed |
NCT03174964 -
Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure
|
Phase 2 | |
Completed |
NCT03161340 -
Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure
|
Phase 2 | |
Not yet recruiting |
NCT01278706 -
Endometrial Biopsy Protocol for In Vitro Fertilization (IVF)
|
N/A | |
Completed |
NCT00750451 -
Low Molecular Weight Heparin in Recurrent Implantation Failure
|
N/A | |
Not yet recruiting |
NCT03690830 -
Use of Metabolomics for the Identification of Endometrial Biomarkers for IRPL and RIF After in Vitro Fertilization
|
N/A | |
Not yet recruiting |
NCT03355937 -
Using Microfluidic Separation Sperm Selection for Unexplained Infertility and Reccurrent Implantation Failure
|
N/A | |
Recruiting |
NCT05169541 -
Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction
|
||
Completed |
NCT04085783 -
PRP in Recurrent Implantation Failure
|
N/A | |
Not yet recruiting |
NCT03365466 -
Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women
|
N/A | |
Active, not recruiting |
NCT03421639 -
Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
|
Phase 4 | |
Recruiting |
NCT04293068 -
Effect of Reproductive Tract Microbiota on Pregnancy Outcome in IVF/ICSI
|